1. Neu, H. C., Chin, N., Labthavikul, P. Comparative in vitro activity and β-lactamase stability of FR 17027, a new orally active cephalosporin. Antimicrobial Agents and Chemotherapy 1984, 26: 174–180.
2. Bowie, W. R., Shaw, C. E., Chan, D. G. W., Boyd, J., Black, W. A. In vitro activity of difloxacin hydrochloride (A-56619), A-56620, and cefixime (CL 284, 635; FK 027) against selected genital pathogens. Antimicrobial Agents and Chemotherapy 1986, 30: 590–593.
3. Saito, I.: Fundamental and clinical studies of FK 027 in gonorrhea: In: Moellering, R. C., Shimada, K., (ed.): A Review of New Oral Cephems, Proceedings of a Workshop Held at the 14th International Congress of Chemotherapy, Kyoto, 1985, p. 55–58.
4. Fuchs, P. C., Jones, R. N., Barry, A. L., Thornsberry, C., Ayers, L. W., Gavan, T. L., Gerlach, E. H. In vitro evaluation of cefixime (FK 027, FR 17027, CL 284 635): spectrum against recent clinical isolates, comparative antimicrobial activity, β-lactamase stability, and preliminary susceptibility testing criteria. Diagnostic Microbiology and Infectious Diseases 1986, 5: 151–162.
5. Grimm, H. Antibakterielle in-vitro-Wirkung neuer oraler Cephalosporine und Empfindlichkeitsprüfung von Cefixim im Agardiffusionstest. Fortschritte der antimikrobiellen und antineoplastischen Chemotherapie 1987, 6–8: 1201–1211.